Ferric carboxymaltose administration in patients with HFrEF and non-anemic iron deficiency significantly improved global longitudinal strain from -12.3% to -15.6% at 4 weeks (p < .001).
Observational (n=43)
No
Does ferric carboxymaltose improve global longitudinal strain in adults with heart failure with reduced ejection fraction and non-anemic iron deficiency?
Ferric carboxymaltose administration in HFrEF patients with non-anemic iron deficiency leads to early improvement in myocardial contractility as measured by global longitudinal strain.
Absolute Event Rate: -15.6% vs -12.3%
p-value: p=<.001
BACKGROUND: Iron deficiency correction with ferric carboxymaltose improves symptoms and reduces rehospitalization in patients with reduced left ventricular ejection fraction. The mechanisms underlying these improvements are poorly understood. This study aimed to determine changes in left ventricular contractility after iron treatment as reflected in global longitudinal strain. METHODS: Prospective single-center study including 43 adults with reduced ejection fraction, non-anemic iron deficiency, and functional class II-III heart failure despite optimal medical treatment. Global longitudinal strain through speckle-tracking echocardiography was measured at baseline and 4 weeks after ferric carboxymaltose. RESULTS: A significant improvement in global longitudinal strain was detected (from -12.3% ± 4.0% at baseline to -15.6% ± 4.1%, p < .001); ferritin and transferrin saturation index had increased, but ejection fraction presented no significant changes (baseline 35.7% ± 4.6%, follow-up 37.2% ± 6.6%, p = .073). CONCLUSIONS: In patients with heart failure and reduced ejection fraction, the correction of iron deficiency with ferric carboxymaltose is associated with an early improvement in global longitudinal strain, possibly suggesting a direct effect of iron correction on myocardial contractility.
Sutil‐Vega et al. (Mon,) conducted a observational in Heart failure with reduced ejection fraction and non-anemic iron deficiency (n=43). Ferric carboxymaltose vs. Baseline was evaluated on Global longitudinal strain (p=<.001). Ferric carboxymaltose administration in patients with HFrEF and non-anemic iron deficiency significantly improved global longitudinal strain from -12.3% to -15.6% at 4 weeks (p < .001).